Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer.

Anticancer research - 1 Jan 2000

Okada Kohji, Shimura Tatsuo, Suehiro Taketoshi, Mochiki Erito, Kuwano Hiroyuki

Abstract excerpt

BACKGROUND: Galectin-3 (gal-3) participates in a variety of biological events, including cell adhesion, proliferation, differentiation and apoptosis. The aim of this study was to determine the relationship of gal-3 expression with clinicopathological findings and prognosis in patients with gastric cancer. PATIENTS AND METHODS: Gal-3 and Ki-67 expressions were assessed by immunohistochemistry in 115 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Nucleus
Share to Galectin 3
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ki-67 Antigen

Share to Neoplasm Staging

Share to Polymorphism, Single-Stranded Conformational

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Stomach Neoplasms

Source

Identifiers

PMID: 16619546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer.PMID 16619546Read ↗

Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.Semantic proximity Read ↗

Silencing of galectin‐3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agentsSemantic proximity Read ↗

Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression.Semantic proximity Read ↗

Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling.Semantic proximity Read ↗

Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.Semantic proximity Read ↗

Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling.Semantic proximity Read ↗

Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer.Semantic proximity Read ↗

Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.Semantic proximity Read ↗

Expression of galectins in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells.Semantic proximity Read ↗

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.Semantic proximity Read ↗

Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.